Inglés

Eligibility Breast Neoplasms NCT01239745

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
postmenopausal females, defined as one from the next :
Descripción

Postmenopausal state

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0232970
1. natural menopause ≥1 year,
Descripción

Menopause Duration

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0567312
UMLS CUI [1,2]
C0449238
2. surgical ovariectomy,
Descripción

Ovariectomy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0029936
3. chemotherapy-induced amenorrhoea ≥ 2 years.
Descripción

Amenorrhea Chemotherapy Induced

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0002453
UMLS CUI [1,2]
C0392920
UMLS CUI [1,3]
C0205263
patients who have had surgical treatment for histologically confirmed breast cancer that was non-metastatic at the time of the initial diagnosis.
Descripción

Operative Surgical Procedure Breast Carcinoma | Neoplasm Metastasis Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0543467
UMLS CUI [1,2]
C0678222
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C0332197
patients who are disease-free after 2 to 3 years of adjuvant tamoxifen treatment.
Descripción

Disease Free Duration | Status post Adjuvant therapy | Tamoxifen

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0332296
UMLS CUI [1,3]
C0449238
UMLS CUI [2,1]
C0231290
UMLS CUI [2,2]
C0677850
UMLS CUI [3]
C0039286
patients whose tumour was estrogen receptor positive (er+).
Descripción

Neoplasm Estrogen receptor positive

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0027651
UMLS CUI [1,2]
C0279754
evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Descripción

Informed Consent | Informed Consent Patient Representative

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2,1]
C0021430
UMLS CUI [2,2]
C0030701
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients for whom aromasin® treatment is contraindicated (see smpc).
Descripción

Medical contraindication Aromasin

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0876723
metastatic breast cancer or a contra lateral tumour.
Descripción

Secondary malignant neoplasm of female breast | Neoplasm Contralateral

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0346993
UMLS CUI [2,1]
C0027651
UMLS CUI [2,2]
C0441988
other concomitant adjuvant endocrine therapy.
Descripción

Hormone Therapy Adjuvant

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C1522673
other concomitant antineoplastic treatment.
Descripción

Cancer treatment

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0920425
participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.
Descripción

Study Subject Participation Status | Investigational New Drugs

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
Volver a la parte superior de la página

Similar models

Eligibility Breast Neoplasms NCT01239745

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Postmenopausal state
Item
postmenopausal females, defined as one from the next :
boolean
C0232970 (UMLS CUI [1])
Menopause Duration
Item
1. natural menopause ≥1 year,
boolean
C0567312 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
Ovariectomy
Item
2. surgical ovariectomy,
boolean
C0029936 (UMLS CUI [1])
Amenorrhea Chemotherapy Induced
Item
3. chemotherapy-induced amenorrhoea ≥ 2 years.
boolean
C0002453 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0205263 (UMLS CUI [1,3])
Operative Surgical Procedure Breast Carcinoma | Neoplasm Metastasis Absent
Item
patients who have had surgical treatment for histologically confirmed breast cancer that was non-metastatic at the time of the initial diagnosis.
boolean
C0543467 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Disease Free Duration | Status post Adjuvant therapy | Tamoxifen
Item
patients who are disease-free after 2 to 3 years of adjuvant tamoxifen treatment.
boolean
C0012634 (UMLS CUI [1,1])
C0332296 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,3])
C0231290 (UMLS CUI [2,1])
C0677850 (UMLS CUI [2,2])
C0039286 (UMLS CUI [3])
Neoplasm Estrogen receptor positive
Item
patients whose tumour was estrogen receptor positive (er+).
boolean
C0027651 (UMLS CUI [1,1])
C0279754 (UMLS CUI [1,2])
Informed Consent | Informed Consent Patient Representative
Item
evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Medical contraindication Aromasin
Item
patients for whom aromasin® treatment is contraindicated (see smpc).
boolean
C1301624 (UMLS CUI [1,1])
C0876723 (UMLS CUI [1,2])
Secondary malignant neoplasm of female breast | Neoplasm Contralateral
Item
metastatic breast cancer or a contra lateral tumour.
boolean
C0346993 (UMLS CUI [1])
C0027651 (UMLS CUI [2,1])
C0441988 (UMLS CUI [2,2])
Hormone Therapy Adjuvant
Item
other concomitant adjuvant endocrine therapy.
boolean
C0279025 (UMLS CUI [1,1])
C1522673 (UMLS CUI [1,2])
Cancer treatment
Item
other concomitant antineoplastic treatment.
boolean
C0920425 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs
Item
participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Volver a la parte superior de la página